Effect of anlotinib combined with camrelizumab on clinical efficacy and short-term prognosis in male patients with advanced gastric cancer

This study aimed to investigate the effects of combining anlotinib with camrelizumab on clinical efficacy and short-term prognosis in male patients with advanced gastric cancer. A total of 88 male patients admitted to our hospital between May 2019 and March 2022 with advanced gastric cancer were included and randomly assigned to Group A (treated with anlotinib alone) or Group B (treated with anlotinib combined with camrelizumab) using the envelope method, with 44 patients in each group. Their clinical efficacy, vascular endothelial growth factor (VEGF) and programmeddeath-1 (PD-1) expression on Cluster of differentiation 4+ (CD4+) and cytotoxic Tlymphocyte (CD8+ T) cells in peripheral blood, immune function parameters, tumor markers, incidence of adverse reactions and survival time were compared. The results showed that the patients in Group B had significantly higher objective response rate (ORR) and disease control rate (DCR), superior PD-1 in VEGF, CD4+ T cells and CD8+ T cells, significantly improved immune function indicators and tumor markers (Carbohydrate antigen 50 (CA50), carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA21-1)), and significantly longer progression-free survival and overall survival than Group A. In addition, no significant difference in the incidence of adverse reactions between the two groups was observed. Therefore, the combination of anlotinib and camrelizumab could be a clinically beneficial treatment option and recommended for male patients with advanced gastric cancer as it can effectively control tumor progression, improve clinical efficacy and prolong their survival without increasing adverse reactions.

Anlotinib; Camrelizumab; Male; Advanced gastric cancer; Clinical efficacy; Short-term prognosis

[1] Rugo HS. Continuing advancements in breast cancer care. Oncology. 2021; 35: 11–13.

[2] de Steur WO, van Amelsfoort RM, Hartgrink HH, Putter H, Meershoek-Klein Kranenbarg E, van Grieken NCT, et al. Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial. Annals of Oncology. 2021; 32: 360–367.

[3] Guo T, Tang XH, Gao XY, Zhou Y, Jin B, Deng ZQ, et al. A liquid biopsy signature of circulating exosome-derived mRNAs, miRNAs and lncRNAs predict therapeutic efficacy to neoadjuvant chemotherapy in patients with advanced gastric cancer. Molecular Cancer. 2022; 21: 216.

[4] Li Y, Xu C, Wang B, Xu F, Ma F, Qu Y, et al. Author correction: proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies. Nature Communications. 2022; 13: 6749.

[5] Li S, Yu W, Xie F, Luo H, Liu Z, Lv W, et al. Neoadjuvant therapy with immune checkpoint blockade, anti-angiogenesis, and chemotherapy for locally advanced gastric cancer. Nature Communications. 2023; 14: 8.

[6] Lee CK, Rha SY, Kim HS, Jung M, Kang B, Che J, et al. A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer. Nature Communications. 2022; 13: 6002.

[7] Koizumi Y, Ahmad S, Ikeda M, Yashima-Abo A, Espina G, Sugimoto R, et al. Helicobacter pylori modulated host immunity in gastric cancer patients with S-1 adjuvant chemotherapy. Journal of the National Cancer Institute. 2022; 114: 1149–1158.

[8] Bonnot PE, Lintis A, Mercier F, Benzerdjeb N, Passot G, Pocard M, et al. Prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CYTO-CHIP study). British Journal of Surgery. 2021; 108: 1225–1235.

[9] af Burén S, Tran TA, Klevebro F, Holstensson M, Axelsson R. A 68Ga-FAPI-46 PET/CT imaging pitfall in assessing residual gastric cancer early after chemotherapy. Clinical Nuclear Medicine. 2022; 47: 644–645.

[10] Zheng S, Wang J, Ding N, Chen W, Chen H, Xue M, et al. Prodrug polymeric micelles integrating cancer-associated fibroblasts deactivation and synergistic chemotherapy for gastric cancer. Journal of Nanobiotechnology. 2021; 19: 381.

[11] Chen Y, Yin J, Zhao L, Zhou G, Dong S, Zhang Y, et al. Reconstruction of the gastric cancer microenvironment after neoadjuvant chemotherapy by longitudinal single-cell sequencing. Journal of Translational Medicine. 2022; 20: 563.

[12] Ding P, Guo H, Sun C, Yang P, Kim NH, Tian Y, et al. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study. BMC Gastroenterology. 2022; 22: 121.

[13] Liu P, Chen J, Zhao L, Hollebecque A, Kepp O, Zitvogel L, et al. PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. OncoImmunology. 2022; 11: 2093518.

[14] Wu C, Qiu Y, Zhang R, Li X, Liang H, Wang M, et al. Association of peripheral basophils with tumor M2 macrophage infiltration and outcomes of the anti-PD-1 inhibitor plus chemotherapy combination in advanced gastric cancer. Journal of Translational Medicine. 2022; 20: 386.

[15] Xiang X, Guo F, Li G, Ma L, Zhu X, Abdulla Z, et al. Efficacy of intra-arterial chemotherapy with sequential anti-PD-1 antibody in unresectable gastric cancer: a retrospective real-world study. Frontiers in Oncology. 2022; 12: 1015962.

[16] Qi Q, Peng Y, Zhu M, Zhang Y, Bao Y, Zhang X, et al. Association between serum levels of 12 different cytokines and short-term efficacy of anti-PD-1 monoclonal antibody combined with chemotherapy in advanced gastric cancer. International Immunopharmacology. 2023; 114: 109553.

[17] Pan Y, Lu L, Liu H, Chen D, Han N, Yao R, et al. Case report: long response to PD-1 blockade after failure of trastuzumab plus chemotherapy in advanced Epstein-Barr virus-associated gastric cancer. Frontiers in Immunology. 2022; 13: 1003859.

[18] Arjmand S, Landau AM, Varastehmoradi B, Andreatini R, Joca S, Wegener G. The intersection of astrocytes and the endocannabinoid system in the lateral habenula: on the fast-track to novel rapid-acting antidepressants. Molecular Psychiatry. 2022; 27: 3138–3149.

[19] Sanchez WN, Pochapski JA, Jessen LF, Ellenberger M, Schwarting RK, Robinson DL, et al. Diazepam attenuates the effects of cocaine on locomotion, 50‐kHz ultrasonic vocalizations and phasic dopamine in the nucleus accumbens of rats. British Journal of Pharmacology. 2022; 179: 1565–1577.

[20] Kim R, An M, Lee H, Mehta A, Heo YJ, Kim K, et al. Early tumor-immune microenvironmental remodeling and response to first-line fluoropyrimidine and platinum chemotherapy in advanced gastric cancer. Cancer Discovery. 2022; 12: 984–1001.

[21] Tang J, Zhang C, Lin J, Duan P, Long J, Zhu H. ALOX5‐5‐HETE promotes gastric cancer growth and alleviates chemotherapy toxicity via MEK/ERK activation. Cancer Medicine. 2021; 10: 5246–5255.

[22] Li Y, Xu C, Wang B, Xu F, Ma F, Qu Y, et al. Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies. Nature Communications. 2022; 13: 5723.

[23] Xu Q, Sun Z, Li X, Ye C, Zhou C, Zhang L, et al. Advanced gastric cancer: CT radiomics prediction and early detection of downstaging with neoadjuvant chemotherapy. European Radiology. 2021; 31: 8765–8774.

[24] Janjigian YY, Van Cutsem E, Muro K, Wainberg Z, Al-Batran S, Hyung WJ, et al. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. Future Oncology. 2022; 18: 2465–2473.

[25] Zhu Y, Wu X, Wang W, Chang X, Zhan D, Diao D, et al. Acupuncture for quality of life in gastric cancer patients undergoing adjuvant chemotherapy. Journal of Pain and Symptom Management. 2022; 63: 210–220.

[26] Guo J, Guo J, Cheng B, Sun X, Zhang H, Ma J. Synergistic effect of stereotactic radiotherapy combined with karelizumab on patients with advanced NSCLC. Journal of Healthcare Engineering. 2022; 2022: 1–6.

[27] Liu H, Li Y, Yao Y, Chen K, Gan J. Meta-analysis of efficacy and safety of karelizumab combined with apatinib in the treatment of advanced gastric cancer. Disease Markers. 2022; 2022: 1–9.

[28] Huang C, Liu H, Hu Y, Sun Y, Su X, Cao H, et al. Laparoscopic vs. open distal gastrectomy for locally advanced gastric cancer. JAMA Surgery. 2022; 157: 9.

[29] Lei ZN, Teng QX, Tian Q, Chen W, Xie Y, Wu K, et al. Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduction and Targeted Therapy. 2022; 7: 358.

[30] Jin X, Liu Z, Yang D, Yin K, Chang X. Recent progress and future perspectives of immunotherapy in advanced gastric cancer. Frontiers in Immunology. 2022; 13: 948647.